Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

3(33%)

Results Posted

50%(1 trials)

Terminated

2(22%)

Phase Distribution

Ph phase_3

22%

Ph phase_1

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 3Large-scale testing

2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(2)

Terminated(2)

Detailed Status

Recruiting2

Completed2

Terminated2

Enrolling by invitation1

Not yet recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 32 (66.7%)

Trials by Status

enrolling_by_invitation111%

not_yet_recruiting111%

active_not_recruiting111%

recruiting222%

completed222%

terminated222%

Recent Activity

3 active trials

Showing 5 of 9

not_yet_recruitingphase_3

A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

NCT07483632

completedphase_3

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

NCT05083923

recruiting

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

NCT05688436

active_not_recruiting

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

NCT05767736

recruiting

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

NCT05658497

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT07483632Phase 3

A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Not Yet Recruiting

NCT05083923Phase 3

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

Completed

NCT05688436

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Recruiting

NCT05767736

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Active Not Recruiting

NCT05658497

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Recruiting

NCT04746976

Study of Diroximel Fumarate in the Real-World Setting

Terminated

NCT04948606

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel